Cargando…
Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies
Chronic hepatitis C (CHC) is a liver disease characterized by infection with the hepatitis C virus (HCV) persisting for more than six months. Patients with CHC often stop pursuing the pegylated interferon (peg-IFN) and ribavirin (RBV) treatment because of the high cost and associated adverse effects...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863289/ https://www.ncbi.nlm.nih.gov/pubmed/27186094 |
_version_ | 1782431455441321984 |
---|---|
author | Wang, Chun-Hsiang Hwang, Yuchi Lin, Eugene |
author_facet | Wang, Chun-Hsiang Hwang, Yuchi Lin, Eugene |
author_sort | Wang, Chun-Hsiang |
collection | PubMed |
description | Chronic hepatitis C (CHC) is a liver disease characterized by infection with the hepatitis C virus (HCV) persisting for more than six months. Patients with CHC often stop pursuing the pegylated interferon (peg-IFN) and ribavirin (RBV) treatment because of the high cost and associated adverse effects. Therefore, it is highly desirable, both clinically and economically, to establish the determinants of response to distinguish responders from nonresponders, and to predict the possible outcomes of the peg-IFN and RBV treatments. The aim of this study was to review recent data on the pharmacogenomics of the drug efficacy of IFN in CHC patients. Single nucleotide polymorphisms (SNPs) can be used to understand the relationship between genetic inheritance and IFN therapeutic response. In the recent advent of scientific research, the genome-wide association study (GWAS), which is an alternative to the candidate-gene approach, is widely utilized to examine hundreds of thousands of SNPs by high-throughput genotyping technologies. In addition to the candidate-gene approach, the GWAS approach has recently been employed to study the determinants of HCV’s response to therapy. Several recent findings have demonstrated that some SNPs in the interleukin 28B gene are closely associated with IFN responsiveness. These results promise to lead to mechanistic findings related to IFN responsiveness in this disease, and will probably have major contributions for individualized medicine and therapeutic decision making. |
format | Online Article Text |
id | pubmed-4863289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48632892016-05-16 Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies Wang, Chun-Hsiang Hwang, Yuchi Lin, Eugene J Exp Pharmacol Review Chronic hepatitis C (CHC) is a liver disease characterized by infection with the hepatitis C virus (HCV) persisting for more than six months. Patients with CHC often stop pursuing the pegylated interferon (peg-IFN) and ribavirin (RBV) treatment because of the high cost and associated adverse effects. Therefore, it is highly desirable, both clinically and economically, to establish the determinants of response to distinguish responders from nonresponders, and to predict the possible outcomes of the peg-IFN and RBV treatments. The aim of this study was to review recent data on the pharmacogenomics of the drug efficacy of IFN in CHC patients. Single nucleotide polymorphisms (SNPs) can be used to understand the relationship between genetic inheritance and IFN therapeutic response. In the recent advent of scientific research, the genome-wide association study (GWAS), which is an alternative to the candidate-gene approach, is widely utilized to examine hundreds of thousands of SNPs by high-throughput genotyping technologies. In addition to the candidate-gene approach, the GWAS approach has recently been employed to study the determinants of HCV’s response to therapy. Several recent findings have demonstrated that some SNPs in the interleukin 28B gene are closely associated with IFN responsiveness. These results promise to lead to mechanistic findings related to IFN responsiveness in this disease, and will probably have major contributions for individualized medicine and therapeutic decision making. Dove Medical Press 2010-06-23 /pmc/articles/PMC4863289/ /pubmed/27186094 Text en © 2010 Wang et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Wang, Chun-Hsiang Hwang, Yuchi Lin, Eugene Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies |
title | Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies |
title_full | Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies |
title_fullStr | Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies |
title_full_unstemmed | Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies |
title_short | Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies |
title_sort | pharmacogenomics of chronic hepatitis c therapy with genome-wide association studies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863289/ https://www.ncbi.nlm.nih.gov/pubmed/27186094 |
work_keys_str_mv | AT wangchunhsiang pharmacogenomicsofchronichepatitisctherapywithgenomewideassociationstudies AT hwangyuchi pharmacogenomicsofchronichepatitisctherapywithgenomewideassociationstudies AT lineugene pharmacogenomicsofchronichepatitisctherapywithgenomewideassociationstudies |